Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 26, 2024; 12(15): 2649-2654
Published online May 26, 2024. doi: 10.12998/wjcc.v12.i15.2649
Cetuximab combined with chemotherapy for simultaneous esophageal squamous cell carcinoma and colon adenocarcinoma: A case report
Xin-Xin Luo, Yu-Xuan Du, Qi-Qing Zhang, Lin Zhang, Shu-Ying Zeng, Zhi-Hong Yu, Peng Shen, Zheng-Quan Feng
Xin-Xin Luo, Lin Zhang, Shu-Ying Zeng, The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang Province, China
Yu-Xuan Du, Qi-Qing Zhang, Zhi-Hong Yu, Zheng-Quan Feng, Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang Province, China
Peng Shen, Department of Medical Oncology, The First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Author contributions: Luo XX, Zhang L and Zeng SY contributed to conceptualization, methodology, data curation and analysis, writing (original draft), and visualization; Luo XX, Du YX, Zhang QQ and Yu ZH contributed to data acquisition; Shen P and Feng ZQ contributed to writing (review and editing); Yu ZH, Shen P and Feng ZQ contributed to supervision. All authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All authors declare no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Zheng-Quan Feng, MD, PhD, Chief Physician, Director, Department of Oncology, Tongde Hospital of Zhejiang Province, No. 234 Gucui Road, Xihu District, Hangzhou 310012, Zhejiang Province, China.
Received: February 16, 2024
Revised: March 15, 2024
Accepted: April 9, 2024
Published online: May 26, 2024
Core Tip

Core Tip: We report a case of a 64-year-old patient diagnosed with synchronous esophageal squamous cell carcinoma and colon adenocarcinoma with liver metastasis. After multi-disciplinary consultations, oxaliplatin + capecitabine chemotherapy and esophageal cancer radiotherapy were initiated. Based on genetic testing, treatment was switched to a regimen of leucovorin + fluorouracil + oxaliplatin and cetuximab for 8 cycles. Subsequently, capecitabine and bevacizumab were administered, and the tumor was stable at the most recent follow-up. This case demonstrates successful treatment of dual primary digestive tract tumors of differing pathological types using the same regimen, which supports non-surgical, simultaneous treatment for synchronous multiple primary cancers.